131 related articles for article (PubMed ID: 21905620)
21. Detection of epidermal growth factor receptor mRNA in peripheral blood of cervical cancer patients.
Mitsuhashi A; Tanaka N; Suzuka K; Matsui H; Seki K; Sekiya S
Gynecol Oncol; 2003 Jun; 89(3):480-5. PubMed ID: 12798715
[TBL] [Abstract][Full Text] [Related]
22. Detection of disseminated urothelial cancer cells in peripheral venous blood by a cytokeratin 20-specific nested reverse transcriptase-polymerase chain reaction.
Fujii Y; Kageyama Y; Kawakami S; Kihara K; Oshima H
Jpn J Cancer Res; 1999 Jul; 90(7):753-7. PubMed ID: 10470288
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic value of the BRAF variant V595E in urine samples, smears and biopsies from canine transitional cell carcinoma].
Aupperle-Lellbach H; Grassinger J; Hohloch C; Kehl A; Pantke P
Tierarztl Prax Ausg K Kleintiere Heimtiere; 2018 Oct; 46(5):289-295. PubMed ID: 30541168
[TBL] [Abstract][Full Text] [Related]
24. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients.
Osman I; Kang M; Lee A; Deng FM; Polsky D; Mikhail M; Chang C; David DA; Mitra N; Wu XR; Sun TT; Bajorin DF
Int J Cancer; 2004 Oct; 111(6):934-9. PubMed ID: 15300806
[TBL] [Abstract][Full Text] [Related]
25. Utility of urothelial mRNA markers in blood for staging and monitoring bladder cancer.
Marín-Aguilera M; Mengual L; Ribal MJ; Ars E; Ríos J; Gázquez C; Villavicencio H; Alcaraz A
Urology; 2012 Jan; 79(1):240.e9-15. PubMed ID: 22055693
[TBL] [Abstract][Full Text] [Related]
26. Immunocytochemical detection of circulating esophageal carcinoma cells by immunomagnetic separation.
Nakamura T; Yasumura T; Hayashi K; Eguchi R; Ide H; Takasaki K; Kasajima T
Anticancer Res; 2000; 20(6C):4739-44. PubMed ID: 11205210
[TBL] [Abstract][Full Text] [Related]
27. Expression of uroplakin Ib and uroplakin III genes in tissues and peripheral blood of patients with transitional cell carcinoma.
Yuasa T; Yoshiki T; Tanaka T; Kim CJ; Isono T; Okada Y
Jpn J Cancer Res; 1998 Sep; 89(9):879-82. PubMed ID: 9818021
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer.
Zieglschmid V; Hollmann C; Mannel J; Albert W; Jaeschke-Melli S; Eckstein B; Hillemann T; Greten TF; Gross E; Böcher O
Anticancer Res; 2007; 27(4A):1823-32. PubMed ID: 17649779
[TBL] [Abstract][Full Text] [Related]
29. Expression profile of cancer-testis genes in transitional cell carcinoma of the bladder.
Yin B; Liu G; Wang XS; Zhang H; Song YS; Wu B
Urol Oncol; 2012; 30(6):886-92. PubMed ID: 21396841
[TBL] [Abstract][Full Text] [Related]
30. Epithelial differentiation antigens and epidermal growth factor receptors in transitional cell bladder carcinoma: correlation with prognosis.
Nakopoulou L; Zervas A; Constantinides C; Deliveliotis C; Stefanaki K; Dimopoulos C
Urol Int; 1995; 54(4):191-7. PubMed ID: 7541921
[TBL] [Abstract][Full Text] [Related]
31. THE SIGNIFICANCE OF EPIDERMAL GROWTH FACTOR RECEPTOR AND SURVIVIN EXPRESSION IN BLADDER CANCER TISSUE AND URINE CYTOLOGY OF PATIENTS WITH TRANSITIONAL CELL CARCINOMA OF THE URINARY BLADDER.
Kehinde EO; Al-Maghrebi M; Anim JT; Kapila K; George SS; Al-Juwaiser A; Memon A
East Afr Med J; 2013 Jan; 90(1):19-27. PubMed ID: 26862626
[TBL] [Abstract][Full Text] [Related]
32. [Expression of melanoma antigen gene in urinary transitional cell carcinomas].
Geng L; Yu LZ; Du P; Ma M; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):667-71. PubMed ID: 16008943
[TBL] [Abstract][Full Text] [Related]
33. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
[TBL] [Abstract][Full Text] [Related]
34. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
35. Urinary cytokeratin 20 as a marker for transitional cell carcinoma.
Rotem D; Cassel A; Lindenfeld N; Mecz Y; Sova Y; Resnick M; Stein A
Eur Urol; 2000 May; 37(5):601-4. PubMed ID: 10765100
[TBL] [Abstract][Full Text] [Related]
36. Urinary cytodiagnosis: can it have a different prognostic implication than a diagnostic test?
Chow NH; Tzai TS; Cheng HL; Chan SH; Lin JS
Urol Int; 1994; 53(1):18-23. PubMed ID: 7974880
[TBL] [Abstract][Full Text] [Related]
37. Detection of upper urinary tract transitional cell carcinoma with ImmunoCyt: a preliminary report.
Lodde M; Mian C; Wiener H; Haitel A; Pycha A; Marberger M
Urology; 2001 Sep; 58(3):362-6. PubMed ID: 11549481
[TBL] [Abstract][Full Text] [Related]
38. Real time reverse transcriptase polymerase chain reaction of urinary cytokeratin 20 detects transitional cell carcinoma cells.
Inoue T; Nakanishi H; Inada K; Hioki T; Tatematsu M; Sugimura Y
J Urol; 2001 Dec; 166(6):2134-41. PubMed ID: 11696722
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of beta-catenin in renal cell cancer and transitional cell cancer with the absence of beta-catenin gene mutations.
Bilim V; Kawasaki T; Katagiri A; Wakatsuki S; Takahashi K; Tomita Y
Clin Cancer Res; 2000 Feb; 6(2):460-6. PubMed ID: 10690524
[TBL] [Abstract][Full Text] [Related]
40. Multifocality of transitional cell carcinoma results from genetic instability of entire transitional epithelium.
Pycha A; Mian C; Hofbauer J; Brössner C; Haitel A; Wiener H; Marberger M
Urology; 1999 Jan; 53(1):92-7. PubMed ID: 9886595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
